Gene therapy has seen significant breakthroughs, particularly in treating genetic disorders such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy. By introducing or correcting defective genes, these therapies can substantially improve muscle function and prolong survival. The approval of Zolgensma for SMA is a notable example, offering a one-time treatment option that has transformative effects.
